What does this research mean for the field?

Nanoparticle-based biosensors, particularly when integrated with artificial intelligence, provide promising rapid and sensitive alternatives to conventional PCR and DNA sequencing for detecting EGFR mutations in non-small cell lung cancer via liquid biopsy. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to explore novel methods for rapid detection of EGFR mutations in non-small cell lung cancer using biosensors and AI.

June 20, 2026Cancer NanotechnologyOpen Access

Artificial intelligence-driven methods and nanoparticle-based biosensors for rapid and sensitive detection of EGFR mutations in non-small cell lung cancer

View Full Paper

Ask AI

Bookmark

Authors

NNNadine Wafik NabihUniversity of Sadat City MNMohamed S. NafieSuez Canal University ABAsaad BabkerGulf Medical University

Discussion

Member takes

Overview

Review summarizes advances in nanoparticle biosensors for EGFR mutations in non-small cell lung cancer, highlighting future clinical applications.

Key Points

The aim is to explore novel methods for rapid detection of EGFR mutations in non-small cell lung cancer using biosensors and AI.
Reviewed advances in nanoparticle-based biosensors for EGFR mutation detection.
Analyzed biosensing approaches using gold nanoparticles, quantum dots, and magnetic nanoparticles.
Discussed challenges in translating these technologies to clinical settings.
Highlighted enhanced signal amplification through AI integration in biosensors.
Noted improved detection sensitivity and reduced response time using advanced nanoparticle methods.
Addressed standardization and regulatory hurdles for clinical implementation.

Cite This Study

Nabih et al. (2026) studied this question.

synapsesocial.com/papers/6a363147db0793dc1a5382e9 https://doi.org/10.1186/s12645-026-00397-8

View Full Paper

Ask AI

Bookmark

June 20, 2026Cancer NanotechnologyOpen Access

Artificial intelligence-driven methods and nanoparticle-based biosensors for rapid and sensitive detection of EGFR mutations in non-small cell lung cancer

View Full Paper

Ask AI

Bookmark

Authors

NNNadine Wafik NabihUniversity of Sadat City MNMohamed S. NafieSuez Canal University ABAsaad BabkerGulf Medical University

Discussion

Member takes

Overview

Review summarizes advances in nanoparticle biosensors for EGFR mutations in non-small cell lung cancer, highlighting future clinical applications.

Key Points

The aim is to explore novel methods for rapid detection of EGFR mutations in non-small cell lung cancer using biosensors and AI.
Reviewed advances in nanoparticle-based biosensors for EGFR mutation detection.
Analyzed biosensing approaches using gold nanoparticles, quantum dots, and magnetic nanoparticles.
Discussed challenges in translating these technologies to clinical settings.
Highlighted enhanced signal amplification through AI integration in biosensors.
Noted improved detection sensitivity and reduced response time using advanced nanoparticle methods.
Addressed standardization and regulatory hurdles for clinical implementation.

Cite This Study

Nabih et al. (2026) studied this question.

synapsesocial.com/papers/6a363147db0793dc1a5382e9 https://doi.org/10.1186/s12645-026-00397-8

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark